Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women
Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women
Several risk factors including high cholesterol contribute to heart disease. We know that
 lowering triglycerides and raising HDL (protective cholesterol) in men reduces the risk for
 heart disease. We expect that women will share this same benefit because the combination of
 high triglycerides and low HDL appears to be a more important risk for heart disease in
 women. Niacin reduces triglycerides and raises HDL. We also expect to see improvement in
 markers of inflammation and clot formation and blood vessel health, which we hypothesize
 should all confer a reduced risk of heart disease in women.

 Women already taking lipid lowering statin will receive niacin therapy. We will measure blood
 lipid levels, markers of inflammation and clotting as well as a non-invasive measure of blood
 vessel reactivity. After 3 months of therapy we will repeat these measures.
Inclusion Criteria:

 -  Stable women on statin therapy with LDL-C between 90-135mg/dl and triglycerides >
 150mg/dl

 Exclusion Criteria:

 -  History of MI, PTCA or surgery within previous 3 months

 -  Currently on Niaspan and unwilling to withdraw Niaspan therapy or known
 intolerance to niacin

 -  Active or known gall bladder disease

 -  Pregnant or nursing women

 -  Significant comorbidity that precludes participation

 -  Significant liver disease, active alcoholism, or LFT >1.5x's ULN at screening

 -  Diabetes or glucose > 126 mg/dl at screening

 -  PI perceived inability to comply with protocol